{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:14:06Z","timestamp":1786115646100,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Acoltremon is a first-in-class transient receptor potential melastatin 8 agonist approved for the treatment of the signs and symptoms of dry eye disease. Given its increasing clinical use following recent approval, post-marketing evaluation of its adverse event (AE) profile is warranted. This study aims to offer insights into the characteristics of acoltremon association with AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionality analysis, including the reporting odds ratio, proportional reporting ratio, information component, and empirical Bayesian geometric mean, were employed in our study. AE signals are determined by using these algorithms. The database for analysis, sourced from the FDA Adverse Event Reporting System, covers the period from the second quarter of 2025 to the first quarter of 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 2,667 AEs associated with acoltremon were identified, with 45 positive signal preferred terms in our study. The three most frequently reported AEs during acoltremon treatment were eye irritation (\n                      <jats:italic>n<\/jats:italic>\n                      = 1,420), eye pain (\n                      <jats:italic>n<\/jats:italic>\n                      = 475) and ocular hyperaemia (\n                      <jats:italic>n<\/jats:italic>\n                      = 226), and the top three AE signals based on reporting odds ratio (ROR) values were eye irritation (380.62, 95% confidence interval (CI): 355.07\u2013408.02), eye pain (129.42, 95% CI: 116.94\u2013143.23) and abnormal sensation in eye (122.70, 95% CI: 78.77\u2013191.14). Drug hypersensitivity (\n                      <jats:italic>n<\/jats:italic>\n                      = 45, ROR 4.15) was also identified as a disproportionality signal in this study. Notably, rhinorrhoea (\n                      <jats:italic>n<\/jats:italic>\n                      = 35, ROR 5.78), nasal discomfort (\n                      <jats:italic>n<\/jats:italic>\n                      = 5, ROR 12.37), ear pruritus (\n                      <jats:italic>n<\/jats:italic>\n                      = 4, ROR 8.09), ophthalmic herpes simplex (\n                      <jats:italic>n<\/jats:italic>\n                      = 3, ROR 57.73), respiratory tract infection viral (\n                      <jats:italic>n<\/jats:italic>\n                      = 3, ROR 8.12) were newly detected disproportionality signals identified. Comparative analysis with other dry eye therapies showed that several ocular AEs were also observed with comparator treatments, whereas some newly detected signals, including rhinorrhoea, nasal discomfort, ear pruritus and ophthalmic herpes simplex were not detected among the comparator drugs. Sensitivity analysis excluding reports with concomitant medications showed that the major disproportionality findings remained generally consistent, although several signals were no longer detected, including ear pruritus, ophthalmic herpes simplex, and respiratory tract infection viral.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study identified potential safety signals associated with acoltremon in the FAERS database. These findings should be interpreted cautiously and warrant further pharmacovigilance and clinical investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1906740","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:20Z","timestamp":1785990260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analyses of acoltremon: a real-world safety assessment based on the the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III: diagnostic methodology","volume":"279","author":"Wolffsohn","year":"2025","journal-title":"Am J Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry eye disease: impact on quality of life and vision","volume":"1","author":"Uchino","year":"2013","journal-title":"Curr Ophthalmol Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1185\/03007995.2011.566264","article-title":"Work productivity loss in patients with dry eye disease: an online survey","volume":"27","author":"Patel","year":"2011","journal-title":"Curr Med Res Opin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jtos.2021.05.006","article-title":"The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants","volume":"21","author":"Morthen","year":"2021","journal-title":"Ocul Surf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos","article-title":"TFOS DEWS II Report Executive Summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"B8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e077344","DOI":"10.1136\/bmj-2023-077344","article-title":"Dry eye disease management","volume":"384","author":"Safir","year":"2024","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40265-024-02016-5","article-title":"Perfluorohexyloctane ophthalmic solution: a review in dry eye disease","volume":"84","author":"Zhuang-Yan","year":"2024","journal-title":"Drugs."},{"key":"B11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICU.0000000000000569","article-title":"Advances in dry eye disease treatment","volume":"30","author":"O'Neil","year":"2019","journal-title":"Curr Opin Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMra1407936","article-title":"Dry eye","volume":"378","author":"Clayton","year":"2018","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ophtha.2025.09.018","article-title":"Acoltremon ophthalmic solution 0003% for signs and symptoms of dry eye disease: results of phase 3 pivotal COMET-2 and COMET-3 studies","volume":"133","author":"Pattar","year":"2026","journal-title":"Ophthalmology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/nm.2264","article-title":"Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea","volume":"16","author":"Parra","year":"2010","journal-title":"Nat Med."},{"key":"B16","unstructured":"FDA Adverse Event Reporting System (FAERS): Data Files"},{"key":"B17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1152\/jn.00523.2012","article-title":"Quantitative characterization reveals three types of dry-sensitive corneal afferents: pattern of discharge, receptive field, and thermal and chemical sensitivity","volume":"108","author":"Hirata","year":"2012","journal-title":"J Neurophysiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.1523\/JNEUROSCI.0654-19.2019","article-title":"Role of TRPM8 channels in altered cold sensitivity of corneal primary sensory neurons induced by axonal damage","volume":"39","author":"Pi\u00f1a","year":"2019","journal-title":"J Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1167\/iovs.03-1366","article-title":"Tear secretion induced by selective stimulation of corneal and conjunctival sensory nerve fibers","volume":"45","author":"Acosta","year":"","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1167\/iovs.16-20033","article-title":"Functional properties of sensory nerve terminals of the mouse cornea","volume":"58","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/j.pain.0000000000000455","article-title":"Abnormal activity of corneal cold thermoreceptors underlies the unpleasant sensations in dry eye disease","volume":"157","author":"Kov\u00e1cs","year":"2016","journal-title":"Pain."},{"key":"B25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e90754","DOI":"10.7759\/cureus.90754","article-title":"Anatomical and functional alterations in nasolacrimal duct obstruction: a comprehensive review","volume":"17","author":"S\u00e1enz Araya","year":"2025","journal-title":"Cureus."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.otc.2016.05.003","article-title":"Eustachian tube function","volume":"49","author":"Ars","year":"2016","journal-title":"Otolaryngol Clin North Am."},{"key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/iovs.64.15.24","article-title":"Loss of TRPM8 exacerbate herpes simplex keratitis infection in mice by promoting the infiltration of CD11b+ Ly6G+ cells and increasing the viral load in the cornea","volume":"64","author":"Feng","year":"2023","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cbin.11483","article-title":"TRPM8 channel augments T-cell activation and proliferation","volume":"45","author":"Acharya","year":"2021","journal-title":"Cell Biol Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/v12040373","article-title":"Antiviral effects of menthol on coxsackievirus B","volume":"12","author":"Taylor","year":"2020","journal-title":"Viruses."},{"key":"B31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/thoraxjnl-2013-203894","article-title":"Rhinovirus upregulates transient receptor potential channels in a human neuronal cell line: implications for respiratory virus-induced cough reflex sensitivity","volume":"69","author":"Abdullah","year":"2014","journal-title":"Thorax."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1906740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:21Z","timestamp":1785990261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1906740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1906740"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1906740","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1906740"}}